Summary of Significant Accounting Policies - License Agreements - RareStone (Details)	1 Months Ended	3 Months Ended					6 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($) item	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($) item	Mar. 31, 2022 USD ($)
Significant Agreements
Equity issued in conjunction with license agreement			$ 18,716,000
RareStone Group Ltd. | License agreement
Significant Agreements
Number of performance obligations | item										2
License agreement commercial manufacturing supply discount							$ 1,286,000		$ 1,286,000
Realized loss on RareStone equity					$ 1,040,000	$ 1,040,000
Loss on RareStone equity investment						300,000
Upfront consideration										$ 8,040,000
Contract with customer liability revenue recognized		$ 0		$ 0			$ 0	$ 0
Number of independent sub studies in patients | item	4
Upfront payment	$ 7,000,000									7,000,000
Equity issued in conjunction with license agreement	1,077,586
Equity recorded at fair value						$ 1,040,000					$ 2,440,000
Aggregate payment upon achievement of development and commercial milestones	$ 62,500,000									$ 62,500,000